# Human HLA-A\*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer Protein, Ultra Low Enteroding Cost No. 1982 AND 19

MHC-HM24MT-UL Cat. No.

Description	
Source	Recombinant Human HPV16 E7(HLA-A*02:01) Tetramer Protein is expressed from HEK293 with His tag and Avitag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin.
	It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and YMLDLQPET peptide.
Accession	P04439-1(HLA-A*02:01)&P61769(B2M)&YMLDLQPET peptide
Molecular Weight	The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Endotoxin	Less than 0.01 EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC
Formulation and	1 Storage

#### Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Storage	-20 to -80°C for 12 months as supplied from date of receipt80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Daalamaaaad	

### Background

HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody.

#### **Assay Data**

#### **Bis-Tris PAGE**




Human HLA-A\*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer on Bis-Tris PAGE under under Non reducing (N) condition. The purity is greater than 95%.

SEC-HPLC



## **Assay Data**



The purity of Human HLA-A\*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer is greater than 95% as determined by SEC-HPLC.